Lorenz Buser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lorenz Buser has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Thomas Hermanns
Department of Urology, University Hospital, University of Zürich, Zürich, Switzerland
4 shared publicationsCedric Poyet
Department of Urology, University Hospital, University of Zürich, Zürich, Switzerland
3 shared publications- Cédric Poyet
Department of Urology, University Hospital of Zürich, Zürich, Switzerland
3 shared publications Peter J. Wild
Institute of Pathology and Molecular Pathology, University of Zurich, Zurich, Switzerland
3 shared publicationsPeter Wild
Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
3 shared publicationsAgnes Beermann
Epigenetics Core Laboratory, Institute of Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
2 shared publications
Latest Publications
- Open Access
- 7 January 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 182, 77-86
Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I–IIA cutaneous melanoma
- 7 January 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 182, 77-86
Open AccessIdentification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I–IIA cutaneous melanoma
- Open Access
- 1 June 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (6) , 1360
Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer—A Retrospective Digital Pathology Study
To evaluate the prognostic value of a modified Immunoscore (mIS) in a cohort of bladder cancer (BC) patients undergoing radical cystectomy (RC), two tissue microarrays of 159 BC patients were immunohistochemically stained for CD3/CD8/FOXP3 and CD45RO to detect Tumor-Infiltrating Lymphocytes (TIL). To predict progression free survival (PFS) and cancer specific survival (CSS), a predictive model cumulatively incorporating all four components was constructed and labeled as mIS. Patients were stratified into two risk groups; “high mIS/favorable risk” and “low mIS/unfavorable risk”. Kaplan–Meier analysis was used to test mIS within each American Joint Committee on Cancer (AJCC) stage group for BC. In a univariable cox regression analysis all single components used for mIS, showed a significant association with CSS. Patients with high mIS (all components) in the AJCC stage IIIa group additionally showed a significantly longer PFS (Hazard Ratio (HR): 2.7; p = 0.008) and CSS (HR: 3.5; p = 0.006) as compared to patients with low mIS. mIS is of prognostic value in BC patients undergoing RC and was able to stratify patients within AJCC stage IIIa and might thus serve as a prognostic marker to guide risk-adapted treatment or follow-up strategies after RC.
- 1 June 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (6) , 1360
Open AccessModified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer—A Retrospective Digital Pathology Study
To evaluate the prognostic value of a modified Immunoscore (mIS) in a cohort of bladder cancer (BC) patients undergoing radical cystectomy (RC), two tissue microarrays of 159 BC patients were immunohistochemically stained for CD3/CD8/FOXP3 and CD45RO to detect Tumor-Infiltrating Lymphocytes (TIL). To predict progression free survival (PFS) and cancer specific survival (CSS), a predictive model cumulatively incorporating all four components was constructed and labeled as mIS. Patients were stratified into two risk groups; “high mIS/favorable risk” and “low mIS/unfavorable risk”. Kaplan–Meier analysis was used to test mIS within each American Joint Committee on Cancer (AJCC) stage group for BC. In a univariable cox regression analysis all single components used for mIS, showed a significant association with CSS. Patients with high mIS (all components) in the AJCC stage IIIa group additionally showed a significantly longer PFS (Hazard Ratio (HR): 2.7; p = 0.008) and CSS (HR: 3.5; p = 0.006) as compared to patients with low mIS. mIS is of prognostic value in BC patients undergoing RC and was able to stratify patients within AJCC stage IIIa and might thus serve as a prognostic marker to guide risk-adapted treatment or follow-up strategies after RC.
- 12 September 2019
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (12) , 1600-1610
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma
Response classification after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma is based on the TNM stage at radical cystectomy. We recently showed that histopathologic tumor regression grades (TRGs) add prognostic information to TNM. Our aim was to validate the prognostic significance of TRG in muscle-invasive bladder cancer in a multicenter setting. We enrolled 389 patients who underwent cisplatin-based chemotherapy before radical cystectomy in 8 centers between 2010 and 2016. Median follow-up was 2.2 years. TRG was determined in radical cystectomy specimens by local pathologists. Central pathology review was conducted in 20% of cases, which were randomly selected. The major response was defined as ≤pT1N0. The remaining patients were grouped into partial responders (≥ypT2N0-3 and TRG 2) and nonresponders (≥ypT2N0-3 and TRG 3). TRG was successfully determined in all cases, and interobserver agreement in central pathology review was high (κ=0.83). After combining TRG and TNM, 47%, 15%, and 38% of patients were major, partial, and nonresponders, respectively. Combination of TRG and TNM showed significant prognostic discrimination of overall survival (major responder: reference; partial responder: hazard ratio 3.5 [95% confidence interval: 1.8-6.8]; nonresponder: hazard ratio 6.1 [95% confidence interval: 3.6-10.3]). This discrimination was superior compared with TNM staging alone, supported by 2 goodness-of-fit criteria (P=0.041). TRG is a simple, reproducible histopathologic measurement of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Integrating TRG with TNM staging resulted in significantly better prognostic stratification than TNM staging alone.
- 12 September 2019
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (12) , 1600-1610
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma
Response classification after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma is based on the TNM stage at radical cystectomy. We recently showed that histopathologic tumor regression grades (TRGs) add prognostic information to TNM. Our aim was to validate the prognostic significance of TRG in muscle-invasive bladder cancer in a multicenter setting. We enrolled 389 patients who underwent cisplatin-based chemotherapy before radical cystectomy in 8 centers between 2010 and 2016. Median follow-up was 2.2 years. TRG was determined in radical cystectomy specimens by local pathologists. Central pathology review was conducted in 20% of cases, which were randomly selected. The major response was defined as ≤pT1N0. The remaining patients were grouped into partial responders (≥ypT2N0-3 and TRG 2) and nonresponders (≥ypT2N0-3 and TRG 3). TRG was successfully determined in all cases, and interobserver agreement in central pathology review was high (κ=0.83). After combining TRG and TNM, 47%, 15%, and 38% of patients were major, partial, and nonresponders, respectively. Combination of TRG and TNM showed significant prognostic discrimination of overall survival (major responder: reference; partial responder: hazard ratio 3.5 [95% confidence interval: 1.8-6.8]; nonresponder: hazard ratio 6.1 [95% confidence interval: 3.6-10.3]). This discrimination was superior compared with TNM staging alone, supported by 2 goodness-of-fit criteria (P=0.041). TRG is a simple, reproducible histopathologic measurement of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Integrating TRG with TNM staging resulted in significantly better prognostic stratification than TNM staging alone.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1632
The expression of ANGPTL2 on tumor vessels predicts outcome in invasive bladder cancer after radical cystectomy
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1632
The expression of ANGPTL2 on tumor vessels predicts outcome in invasive bladder cancer after radical cystectomy
- 1 August 2018
- Published by Hogrefe Publishing Group in Praxis
- Vol. 107 (17-18) , 987-988
CME-Antworten zu «Sekundärehämophagozytische Lymphohistiozytose», Praxis Nr. 16
- 1 August 2018
- Published by Hogrefe Publishing Group in Praxis
- Vol. 107 (17-18) , 987-988
CME-Antworten zu «Sekundärehämophagozytische Lymphohistiozytose», Praxis Nr. 16
- 1 August 2018
- Published by Hogrefe Publishing Group in Praxis
- Vol. 107 (16) , 873-881
CME: Sekundäre hämophagozytische Lymphohistiozytose
Zusammenfassung. Sekundäre hämophagozytische Lymphohistiozytose-Syndrome beschreiben eine vom Erscheinungsbild heterogene Gruppe überschiessender entzündlicher Reaktionen des Immunsystems, die durch Hyperinflammation mit Vermehrung zytotoxischer T-Lymphozyten und Makrophagen bei gesteigerter Hämophagozytose-Aktivität reagieren. Das sekundäre hämophagozytische Lymphohistiozytose-Syndrom wird häufig unterdiagnostiziert, was zu einer hohen Morbidität und Mortalität beiträgt. Die Abfrage der etablierten diagnostischen Kriterien in einem systematischen Abklärungsalgorithmus soll helfen, durch frühzeitige Diagnosestellung und Initiation einer passenden Therapie höhere Heilungsraten zu erreichen.
- 1 August 2018
- Published by Hogrefe Publishing Group in Praxis
- Vol. 107 (16) , 873-881
CME: Sekundäre hämophagozytische Lymphohistiozytose
Zusammenfassung. Sekundäre hämophagozytische Lymphohistiozytose-Syndrome beschreiben eine vom Erscheinungsbild heterogene Gruppe überschiessender entzündlicher Reaktionen des Immunsystems, die durch Hyperinflammation mit Vermehrung zytotoxischer T-Lymphozyten und Makrophagen bei gesteigerter Hämophagozytose-Aktivität reagieren. Das sekundäre hämophagozytische Lymphohistiozytose-Syndrom wird häufig unterdiagnostiziert, was zu einer hohen Morbidität und Mortalität beiträgt. Die Abfrage der etablierten diagnostischen Kriterien in einem systematischen Abklärungsalgorithmus soll helfen, durch frühzeitige Diagnosestellung und Initiation einer passenden Therapie höhere Heilungsraten zu erreichen.
- Open Access
- 11 April 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 6051
Author Correction: Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
- 11 April 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 6051
Open AccessAuthor Correction: Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
- 1 March 2018
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (3) , 94.e15-94.e21
p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models
- 1 March 2018
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (3) , 94.e15-94.e21
p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models
- Open Access
- 22 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-14
Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis
Urothelial carcinoma (UC), the most common cancer of the urinary bladder causes severe morbidity and mortality, e.g. about 40.000 deaths in the EU annually, and incurs considerable costs for the health system due to the need for prolonged treatments and long-term monitoring. Extensive aberrant DNA methylation is described to prevail in urothelial carcinoma and is thought to contribute to genetic instability, altered gene expression and tumor progression. However, it is unknown how this epigenetic alteration arises during carcinogenesis. Intact methyl group metabolism is required to ensure maintenance of cell-type specific methylomes and thereby genetic integrity and proper cellular function. Here, using two independent techniques for detecting DNA methylation, we observed DNA hypermethylation of the 5′-regulatory regions of the key methyl group metabolism genes ODC1, AHCY and MTHFR in early urothelial carcinoma. These hypermethylation events are associated with genome-wide DNA hypomethylation which is commonly associated with genetic instability. We therefore infer that hypermethylation of methyl group metabolism genes acts in a feed-forward cycle to promote additional DNA methylation changes and suggest a new hypothesis on the molecular etiology of urothelial carcinoma.
- 22 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-14
Open AccessAberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis
Urothelial carcinoma (UC), the most common cancer of the urinary bladder causes severe morbidity and mortality, e.g. about 40.000 deaths in the EU annually, and incurs considerable costs for the health system due to the need for prolonged treatments and long-term monitoring. Extensive aberrant DNA methylation is described to prevail in urothelial carcinoma and is thought to contribute to genetic instability, altered gene expression and tumor progression. However, it is unknown how this epigenetic alteration arises during carcinogenesis. Intact methyl group metabolism is required to ensure maintenance of cell-type specific methylomes and thereby genetic integrity and proper cellular function. Here, using two independent techniques for detecting DNA methylation, we observed DNA hypermethylation of the 5′-regulatory regions of the key methyl group metabolism genes ODC1, AHCY and MTHFR in early urothelial carcinoma. These hypermethylation events are associated with genome-wide DNA hypomethylation which is commonly associated with genetic instability. We therefore infer that hypermethylation of methyl group metabolism genes acts in a feed-forward cycle to promote additional DNA methylation changes and suggest a new hypothesis on the molecular etiology of urothelial carcinoma.